Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s12931-015-0276-5 http://scihub22266oqcxt.onion/10.1186/s12931-015-0276-5 C4581488!4581488!26400368     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Respir+Res 2015 ; 16 (ä): ä Nephropedia Template TP {{tp|p=26400368|t=2015. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis |pdf=|usr=}}{{26400368}} gab.com Text Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis JO: Respir Res http://www.kidney.de/pget.php?&tw=1&pmid=26400368 #FOAvip Background: Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterised by dyspnea and loss of lung function. Methods: Using pooled data from the replicate, randomized, 52-week, placebo-controlled INPULSIS® trials, we characterized the safety and tolerability of nintedanib 150 mg twice daily in patients with IPF and described how adverse events were managed during these trials. Results: One thousand and sixty- one patients were treated (nintedanib 638; placebo 423). Higher proportions of patients in the nintedanib group than the placebo group had ?1 dose reduction to 100 mg bid (27.9 % versus 3.8 %) or treatment interruption (23.7 % versus 9.9 %). Adverse events led to permanent treatment discontinuation in 19.3 % and 13.0 % of patients in the nintedanib and placebo groups, respectively. Diarrhea was the most frequent adverse event, reported in 62.4 % of patients in the nintedanib group versus 18.4 % in the placebo group; however, only 4.4 % of nintedanib-treated patients discontinued trial medication prematurely due to diarrhea. Monitoring of liver enzymes before and periodically during nintedanib treatment was recommended so that liver enzyme elevations could be managed through dose reduction or treatment interruption. Conclusion: Nintedanib had a manageable safety and tolerability profile in patients with IPF. Recommendations for adverse event management minimized permanent treatment discontinuations in the INPULSIS® trials. Trial registration: clinicaltrials.gov NCT01335464 and NCT01335477 Electronic supplementary material: The online version of this article (doi:10.1186/s12931-015-0276-5) contains supplementary material, which is available to authorized users. Twit Text FOAVip Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis ????Respir Res http://www.kidney.de/pget.php?&tw=1&pmid=26400368 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26400368 #FOAvip English Wikipedia <ref>{{Cite pmid|26400368}}</ref> Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis #MMPMID26400368 Corte T; Bonella F; Crestani B; Demedts MG; Richeldi L; Coeck C; Pelling K; Quaresma M; Lasky JA Respir Res 2015[]; 16 (ä): ä PMID26400368show ga Background: Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterised by dyspnea and loss of lung function. Methods: Using pooled data from the replicate, randomized, 52-week, placebo-controlled INPULSIS® trials, we characterized the safety and tolerability of nintedanib 150 mg twice daily in patients with IPF and described how adverse events were managed during these trials. Results: One thousand and sixty- one patients were treated (nintedanib 638; placebo 423). Higher proportions of patients in the nintedanib group than the placebo group had ?1 dose reduction to 100 mg bid (27.9 % versus 3.8 %) or treatment interruption (23.7 % versus 9.9 %). Adverse events led to permanent treatment discontinuation in 19.3 % and 13.0 % of patients in the nintedanib and placebo groups, respectively. Diarrhea was the most frequent adverse event, reported in 62.4 % of patients in the nintedanib group versus 18.4 % in the placebo group; however, only 4.4 % of nintedanib-treated patients discontinued trial medication prematurely due to diarrhea. Monitoring of liver enzymes before and periodically during nintedanib treatment was recommended so that liver enzyme elevations could be managed through dose reduction or treatment interruption. Conclusion: Nintedanib had a manageable safety and tolerability profile in patients with IPF. Recommendations for adverse event management minimized permanent treatment discontinuations in the INPULSIS® trials. Trial registration: clinicaltrials.gov NCT01335464 and NCT01335477 Electronic supplementary material: The online version of this article (doi:10.1186/s12931-015-0276-5) contains supplementary material, which is available to authorized users. äSafety, tolerability and appropriate use of nintedanib in idiopathic p(epmc).pdf DeepDyve Pubget Overpricing